Loading
Trials ordered by the number of people their record says were enrolled, randomised, analysed or treated. Top 50 of 5,892 trials with a value; ties are broken by name. 5,892 of 5,969 trials carry an enrolment figure (99%).
| # | Trial | Enrolment | Phase and cancer |
|---|---|---|---|
| 1 | AgeX | 4,000,000 enrolled | Phase 3 · Breast cancer (all types) |
| 2 | UKCTOCS | 202,638 enrolled | Phase 3 · Ovarian cancer |
| 3 | Kerala oral cancer visual screening trial (Trivandrum) | 191,873 enrolled | Phase 3 · Head and neck squamous cell carcinoma |
| 4 | UK Flexible Sigmoidoscopy Screening Trial | 170,432 randomised | Phase 3 · Colorectal cancer |
| 5 | Nottingham faecal occult blood screening trial | 152,850 randomised | Phase 3 · Colorectal cancer |
| 6 | Mumbai VIA cervical screening trial (Tata Memorial) | 151,538 enrolled | Phase 3 · Cervical cancer |
| 7 | NHS-Galleri | 142,250 randomised | Phase 3 · Lung cancer (all types) |
| 8 | Osmanabad cervical screening trial (HPV testing vs cytology vs VIA) | 131,746 enrolled | Phase 3 · Cervical cancer |
| 9 | MASAI (Mammography Screening with Artificial Intelligence) | 105,934 randomised | Phase 3 · HR-positive / HER2-negative breast cancer |
| 10 | NordICC (Nordic-European Initiative on Colorectal Cancer) | 84,585 analysed | Phase 3 · Colorectal cancer |
| 11 | iStopMM | 75,422 enrolled | Observational study · Multiple myeloma |
| 12 | Funen faecal occult blood screening trial | 61,933 randomised | Phase 3 · Colorectal cancer |
| 13 | ScreenTrustCAD | 55,581 analysed | Observational study · HR-positive / HER2-negative breast cancer |
| 14 | NLST & NELSON (low-dose CT screening) | 53,454 enrolled | Phase 3 · Non-small-cell lung cancer |
| 15 | Childhood Cancer Survivor Study (CCSS) | 50,000 enrolled | Observational study · Acute lymphoblastic leukaemia |
| 16 | PREEMPT CRC | 48,995 enrolled | Observational study · Colorectal cancer |
| 17 | Minnesota Colon Cancer Control Study | 46,551 randomised | Phase 3 · Colorectal cancer |
| 18 | ECLIPSE (Shield blood test) | 44,467 enrolled | Observational study · Colorectal cancer |
| 19 | PATHFINDER 2 | 35,883 enrolled | Observational study |
| 20 | VITAL (VITamin D and OmegA-3 TriaL) | 25,871 enrolled | Phase 3 |
| 21 | Vanguard Study (NCI Cancer Screening Research Network) | 24,000 enrolled | Platform trial |
| 22 | BLUE-C | 20,176 enrolled | Observational study · Colorectal cancer |
| 23 | PRECEDE | 20,000 enrolled | Observational study · Pancreatic ductal adenocarcinoma |
| 24 | SCAN-B (Sweden Cancerome Analysis Network - Breast) | 20,000 enrolled | Observational study · Breast cancer (all types) |
| 25 | ASPREE (ASPirin in Reducing Events in the Elderly) | 19,114 enrolled | Phase 3 |
| 26 | PATRICIA | 18,644 randomised | Phase 3 · Cervical cancer |
| 27 | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years | 18,000 enrolled | Phase 3 · Metastatic cancer (cancer that has spread) |
| 28 | GÖTEBORG-2 (MRI-based prostate cancer screening) | 17,980 enrolled | Phase 3 · Prostate cancer |
| 29 | IARC India HPV vaccine dose study (one, two or three doses) | 17,729 enrolled | Observational study · Cervical cancer |
| 30 | TRANSFORM | 16,000 enrolled | Phase 3 · Prostate cancer |
| 31 | A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years | 13,500 enrolled | Phase 3 · Metastatic cancer (cancer that has spread) |
| 32 | IDEA collaboration | 12,834 analysed | Phase 3 · Colorectal cancer |
| 33 | SUMMIT (lung health check study) | 12,773 registered | Observational study · Non-small-cell lung cancer |
| 34 | Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors | 12,000 enrolled | Phase 3 · Lung cancer (all types) |
| 35 | STAMPEDE | 11,992 enrolled | Platform trial · Prostate cancer |
| 36 | Add-Aspirin | 11,000 enrolled | Phase 3 · Colorectal cancer |
| 37 | TAILORx | 10,273 enrolled | Phase 3 · HR-positive / HER2-negative breast cancer |
| 38 | CAMBRIA-1 & CAMBRIA-2 | 10,000 enrolled | Phase 3 · HR-positive / HER2-negative breast cancer |
| 39 | EUROPAC | 10,000 enrolled | Observational study · Pancreatic ductal adenocarcinoma |
| 40 | DeeP-C | 9,989 enrolled | Observational study · Colorectal cancer |
| 41 | A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males | 9,000 enrolled | Phase 3 · Penile cancer |
| 42 | HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab) | 9,000 enrolled | Phase 3 · HER2-positive breast cancer |
| 43 | The Cancer of the Pancreas Screening-5 CAPS5)Study | 9,000 enrolled | Phase 3 · Pancreatic ductal adenocarcinoma |
| 44 | YLST | 8,847 registered | Phase 3 · Non-small-cell lung cancer |
| 45 | A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer | 8,000 enrolled | Phase 3 · Metastatic cancer (cancer that has spread) |
| 46 | Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | 8,000 enrolled | Phase 3 · Cervical cancer |
| 47 | IBIS-I (International Breast Intervention Study I) | 7,154 enrolled | Phase 3 · Breast cancer (all types) |
| 48 | PALLAS & PENELOPE-B | 6,862 enrolled | Phase 3 · HR-positive / HER2-negative breast cancer |
| 49 | MINDACT | 6,693 enrolled | Phase 3 · HR-positive / HER2-negative breast cancer |
| 50 | International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia | 6,136 enrolled | Phase 3 · Leukaemia (all types) |
5,842 more trials have a value below the top 50; the full list of trials is at /trials/.
Reads the enrolled field and the enrolledBasis field that says what the number counts (the registry figure by default, or the randomised, analysed, treated or registered population from the primary paper). Numbers from different bases are placed on one scale, so a registry total and a randomised count sit side by side. The context column gives the phase and the first cancer the trial names.
Coverage. 5,892 of 5,969 trials carry an enrolment figure (99%). Rows with a value of zero are not listed. Nothing is weighted, imputed or averaged; the ordering is by the number shown, then by name.
Machine-readable copy: /rankings/trials-by-enrolment/data.json. Registry: src/lib/rankings.ts.